Response to Letter Regarding Article, “Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease: The Siegburg First-in-Man Study”
Key result
Percutaneous implantation of the CoreValve prosthesis in high-risk patients demonstrated a reduction in perioperative mortality from 42.9% in the first 7 cases to 11.1% in the subsequent 18 cases.
Why the study?
Does percutaneous implantation of the CoreValve Self-Expanding Valve Prosthesis improve perioperative mortality compared to surgical aortic valve replacement in high-risk patients with severe aortic valve stenosis?
Population
High-risk patients with severe aortic valve stenosis
Comparison
Percutaneous implantation of the CoreValve… vs On-pump surgical aortic valve replacement
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
This response defends the early safety and feasibility of percutaneous aortic valve replacement in high-risk patients who are often denied surgery.
Structured PICO
Does percutaneous implantation of the CoreValve Self-Expanding Valve Prosthesis improve perioperative mortality compared to surgical aortic valve replacement in high-risk patients with severe aortic valve stenosis?
P
Population
25 high-risk patients with aortic valve disease undergoing percutaneous aortic valve replacement in a first-in-man experience.
I
Intervention
Percutaneous implantation of the CoreValve Self-Expanding Valve Prosthesis
C
Comparator
On-pump surgical aortic valve replacement
O
Outcome
Perioperative mortalityhard clinical
Main Result
Absolute Event Rate: 11.1% vs 42.9%
This response defends the early safety and feasibility of percutaneous aortic valve replacement in high-risk patients who are often denied surgery.
Limitations
- Technique is in its infancy
- Requires confirmation of safety and efficacy in larger series
Cite This Study
Grube et al. (2007) conducted a letter in High-risk patients with aortic valve disease (n=25). Percutaneous implantation of the CoreValve Self-Expanding Valve Prosthesis vs. First compassionate use cases was evaluated on Perioperative mortality. Percutaneous implantation of the CoreValve prosthesis in high-risk patients demonstrated a reduction in perioperative mortality from 42.9% in the first 7 cases to 11.1% in the subsequent 18 cases.